Skip to content
Politically.com Search all
Menu

2026 · 3rd Quarter (July 1 - Sep 30)

BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY)

Filed by BLOOD CANCER UNITED (FKA THE LEUKEMIA & LYMPHOMA SOCIETY).

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-10-22 06:41:42 UTC.

Source-reported fields

Filing overview

Type
3rd Quarter - Report
Posted
Oct 20, 2026
Income
Not reported
Expenses
$120,000.00
Filing UUID
485fbeb7-221b-4799-bfe5-a2592c7e22d1
Termination date
Not reported

Expense method: A

Literal source text

Lobbying issues and bill citations

HCR · Health Issues

HJRes 197 / SJRes 197, CRA related to the 2027 NBPP; HR 247 / S 46, Health Care Affordability Act; HR 6867 / S 3562, the NIH Clinical Trial Integrity Act; HR 3521 / S 4440, the Clinical Trial Modernization Act; HR 4710 / S 2420, No Surprises Act Enforcement Act; HR 5526 / S 1954, Biosimilar Red Tape Elimination Act; HR 5582 / S 2355, the Patients Deserve Price Tags Act; HR 6248 / S 4027, Healthy Competition for Better Care Act HR 6485 / S 43, Skinny Labels, Big Savings Act; HR 6867 / S 3562, NIH Clinical Trial Integrity Act; HR 7895, the PBM Kickback Prohibition Act; HR 8879 / S 4509, Patients Before Monopolies Act; HR 8908, the STOP GAMES Act; HR 9393, Lower Costs, More Transparency Act; HR 9396, the Prior Authorization Accountability Act; HR 9397, the Premium Transparency Act; HR 9645, the Health Care Price Certainty for All Americans Act; HR 9661 / S 1414, the Expedited Access to Biosimilars Act; HR 10370, the AIM to Cure Kids with Cancer Act; HR 10788, the Lower Premiums, Faster Payments Act; S 976, the Insurance Fraud Accountability Act; S 1041, Affordable Prescriptions for Patients Act; S 1095, Stop STALLING Act; S 1096, Preserve Access to Affordable Generics & Biosimilars Act S 1097, Interagency Patent Coordination & Improvements Act; S 2658, Medication Affordability & Patent Integrity Act; S 3014, Ensuring Timely Access to Generics Act; S 3822, the Break Up Big Medicine Act Policies to address the expiration of the enhanced Advanced Premium Tax Credits; Policies to improve transparency in hospital and insurer costs and finances; Policies to streamline pediatric patient access to subspecialist care via telemedicine; Policies to protect patients and consumers from junk insurance, including short-term limited duration insurance; Policies related to modernization of clinical trials; Policies related to the 2027 FDA user fee agreements; Implementation of the No Surprises Act; Policies related to oversight of insurance agents and brokers; Oversight and patient impact of the 340B program; Policies related to consolidation within the healthcare sector;

Literal federal measure citations: HJRes 197, SJRes 197, HR 247, S 46, HR 6867, S 3562, HR 3521, S 4440, HR 4710, S 2420, HR 5526, S 1954, HR 5582, S 2355, HR 6248, S 4027, HR 6485, S 43, HR 6867, S 3562, HR 7895, HR 8879, S 4509, HR 8908, HR 9393, HR 9396, HR 9397, HR 9645, HR 9661, S 1414, HR 10370, HR 10788, S 976, S 1041, S 1095, S 1096, S 1097, S 2658, S 3014, S 3822

MMM · Medicare/Medicaid

HR 3514 / S 1816, the Improving Seniors Timely Access to Care Act; HR 5243, a bill to increase data transparency for supplemental benefits under Medicare Advantage; HR 8375 / S 4384, the Medicare Advantage Improvement Act; HR 9392, Medicare Advantage Cost Transparency Act; S 1105, No UPCODE Act; S 1629, Same Care, Lower Cost Act; S 1936, Improving Access to Transfusion Care for Patients Act; S 4886, Medicare Cost Cap Act; CMS Interim Final Rule on Medicaid Work Requirements; Regulatory and legislative proposals to expand site-neutral payment in Medicare; Implementation of the Accelerating Kids Access to Care Act (HR 1509, S 752) Regulatory proposals related to most-favored nation drug pricing; Issues related to the cost of care, including consolidation and anti-competitive contracting

Literal federal measure citations: HR 3514, S 1816, HR 5243, HR 8375, S 4384, HR 9392, S 1105, S 1629, S 1936, S 4886, HR 1509, S 752

BUD · Budget/Appropriations

HR 6500, the Continuing Appropriations and Extensions Act, 2027; HR 9495, FY2027 appropriations for DOD, specifically provisions related to medical research; HR 9260, FY2027 appropriations for HHS, specifically provisions related to medical research;

Literal federal measure citations: HR 6500, HR 9495, HR 9260

MED · Medical/Disease Research/Clinical Labs

HR 6500, the Continuing Appropriations and Extensions Act, 2027; HR 7173, Follow the Science Act; HR 9495, FY2027 appropriations for DOD, specifically provisions related to medical research; HR 9260, FY2027 appropriations for HHS, specifically provisions related to medical research; HR 9632, Accelerating Innovation (AI) for Kids with Cancer Act; S 4494, American Cures Act; OMB Proposed Uniform Grants Regulation; Policies to enable international collaboration by NIH grantees; Policies to maintain the NIHs incremental grant funding model;

Literal federal measure citations: HR 6500, HR 7173, HR 9495, HR 9260, HR 9632, S 4494

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.